---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-042570"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:24:09.214587+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty

## Summary
- License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.
- Avenue to receive $2M total within 90 days: $1M due in 30 days, $1M due in 90 days.
- Potential future payments: up to $5M development milestones, up to $17M commercial milestones, 1.75% royalty on net sales.
- Avenue repurchases 14,777 shares from AnnJi for $1.00 aggregate and pays $0.2M for AnnJi legal expenses.
- 48-month non-compete for competing products in US, Canada, EU, UK, and Israel after termination.

## SEC filing metadata
- accession: 0001104659-25-042570
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465925042570/0001104659-25-042570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465925042570/tm2513615d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-042570
- JSON: https://secwatch.observer/filing/0001104659-25-042570.json
- Plain text: https://secwatch.observer/filing/0001104659-25-042570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.